VAQTA® is an inactivated hepatitis A vaccine developed by Merck & Co., Inc. This vaccine plays a crucial role in preventing hepatitis A virus (HAV) infection, a contagious liver disease that can cause mild to severe illness. Here we will discuss its formulation, uses, advantages, side effects, dosage, precautionary measures, year of invention, company information, and pricing in the UK and USA.
Formulation of VAQTA®
VAQTA® is formulated as an inactivated vaccine containing:
- Inactivated Hepatitis A Virus: The active component that stimulates an immune response.
- Excipients: Stabilizers and preservatives to maintain the vaccine’s effectiveness and shelf life.
Uses of VAQTA®
VAQTA® is primarily used for:
- Hepatitis A Prevention: It is indicated for the immunization of individuals aged 12 months and older at risk of hepatitis A infection. This includes travelers to areas with high rates of HAV transmission and individuals with certain medical conditions.
Advantages of VAQTA®
- Effective Protection: VAQTA® provides effective immunity against hepatitis A, significantly reducing the risk of infection.
- Long-lasting Immunity: A single dose generally confers long-term immunity, with booster doses only recommended for specific populations.
- Well-tolerated: Most individuals experience minimal side effects, making it suitable for various age groups.
Side Effects of VAQTA®
While VAQTA® is considered safe, some recipients may experience side effects, which can include:
- Pain at the injection site
- Mild fever
- Fatigue
- Headache
Dosage of VAQTA®
The dosing schedule for VAQTA® is as follows:
- For Adults and Children over 12 months: A single dose of 0.5 mL administered intramuscularly.
- Booster Dose: A second dose is recommended 6 to 18 months after the first dose for long-term protection.
Precautionary Measures of VAQTA®
Before vaccination with VAQTA®, healthcare providers should consider the following:
- Allergies: Assess for any history of severe allergic reactions to components of the vaccine.
- Immunocompromised Patients: Discuss the risks and benefits of vaccination in patients with weakened immune systems.
- Pregnancy and Breastfeeding: Although generally considered safe, pregnant or breastfeeding individuals should consult their healthcare provider before vaccination.
Year of Invention of VAQTA®
VAQTA® was first licensed for use in the United States in 1995, representing a significant advancement in public health by providing a preventive measure against hepatitis A.
Company Information of VAQTA®
Merck & Co., Inc., also known as MSD outside the USA and Canada, is a leading global healthcare company committed to improving health through research and innovation. Founded in 1891, Merck has a strong portfolio of vaccines and medications that address various health challenges worldwide. VAQTA® exemplifies their dedication to infectious disease prevention.
Price in USA and UK of VAQTA®
The cost of VAQTA® can vary based on healthcare plans and regional pricing. In the USA, the average price for a single dose is approximately $100, while in the UK, the cost can range from £40 to £80 per dose, depending on the provider and location.
Conclusion
VAQTA® (Hepatitis A Vaccine, Inactivated) is a vital tool in preventing hepatitis A infection, particularly for at-risk populations. Its efficacy, long-lasting immunity, and generally favorable side effect profile make it a cornerstone of public health strategies. For personalized recommendations and further information about hepatitis A vaccination, consult your healthcare provider.
